Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q3 EPS of ($0.51), $0.18 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $440 thousand versus the consensus estimate of $755 thousand.

For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.